AstraZeneca, which carries out much of its quality testing of new medicines in the UK, says it is unable to await the outcome of Brexit talks and will carry out quality testing in Sweden as well.
Executive Vice President of Global Operations and IT Pam Cheng tells DN that Brexit will add extra costs for the company and it will have to employ more people in Sweden, although she is unable to give an exact figure at present.
Her message to the Swedish government is to simplify the rules for those wanting to move to Sweden to work. She would also like to see a “more competitive” income tax on labour for foreign expertise.
Cheng has been in Södertälje for the inauguration of Södertälje Science Park and KTH Södertälje, which will bring together 1,200 researchers and students. AstraZeneca is one of a number of partners investing in the park.
We are a small, but qualified team of graduates in politics, economics, English and classics dedicated to providing quality news digests in English that offer readers a first-hand look at the most important topics covered by the Swedish press. Here you will find a selection of the articles that are published in our Swedish Press Review.